WinQure Medicine has been featured in this month’s Member Spotlight by EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs, highlighting our approach to making precision ASO therapies commercially viable for ultra-rare genetic diseases.
The technologies needed to develop precision genetic therapies already exist. The challenge is creating regulatory and reimbursement frameworks that make their development commercially sustainable when each therapy serves a small, genetically defined patient population.
WinQure is building a development model specifically for this challenge, combining precision ASO science with a scalable platform designed to advance therapies across multiple ultra-rare diseases.
We are proud to work alongside EUCOPE and the broader European rare-disease community to help shape an environment where scientific progress can translate into sustainable therapies for patients with the greatest unmet need.